Loading provider…
Loading provider…
Nephrology Physician in Torrance, CA
NPI: 1467431122Primary Practice Location
Trc Harbor UCLA Mfi Total Renal Dialysis Center
21836 Normandie Ave, Torrance, CA
Primary Employer
Prohealth Partners a Medical Group
prohealthpartners.com
HQ Phone
Get M.D. Sharon's Phone Numberphone_androidMobile
Get M.D. Sharon's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1977 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Nephrology
SUNY Downstate Health Sciences University
downstate.edu
Medical School
Until 1976
Los Angeles County-Harbor-UCLA Medical Center
Fellowship • Nephrology
1981 - 1982
Loma Linda University Health Education Consortium
Residency • Internal Medicine
1977 - 1980
Zucker School of Medicine at Hofstra/Northwell
Internship • Internal Medicine
1976 - 1977
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 90960Dialysis services (4 or more physician visits per month), patient 20 years of age and older | 14 | 118 |
| 2 | 90961Dialysis services (2-3 physician visits per month), patient 20 years of age and older | 11 | 24 |
'Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With
Authors: Radko Komers, Debbie S. Gipson, Peter T. Nelson, Sharon G. Adler, Tarak Srivastava
Publication Date: 2017-07
Comprehensive approach to diabetic nephropathy.
Authors: Satirapoj, Bancha, Adler, Sharon G
Journal: Kidney Res Clin Pract
Publication Date: 2014-09-10
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary
Authors: Kevin Lemley
Publication Date: 2013-04
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib